Project cooperationUpdated on 26 June 2025
Preclinical Immuno-modulatory Drug Development in Oncology
About
The native immune system and particularly tumor associated macrophages (TAMs) are critical in driving response to cancer therapies. Abbmira designs novel synthetic small molecule compounds against a specific molecular target of macrophages that activate TAMs to exert direct anti-tumoral action, whilst signaling to the rest of the immune system to fight the cancer also.
Stage
- Proposal Idea
- Proposal under Development
Topic
- MSCA-PF2025
- MSCA-DN2025
Type
- POSTDOCTORAL FELLOWSHIP: Looking for an Institution for Secondment
- DOCTORAL NETWORK: Looking for Partner/s (Beneficiaries or Associated Partners)
Organisation
Similar opportunities
Expertise
Preclinical Immuno-Modulatory Drug Development in Oncology
- CHE - Chemistry
- LIF - Life Sciences
- DOCTORAL NETWORKS: Hosting Doctoral Candidates / Secondments / Trainings
- POSTDOCTORAL FELLOWSHIPS: Hosting Postdoctoral Candidates / Secondments / Placements
Marc Creus
CEO at abbmira therapeutics AG
Basel, Switzerland
Project cooperation
MSCA-PF: Maxillofacial Oncology Research Group
- MSCA-PF2025
- Proposal Idea
- POSTDOCTORAL FELLOWSHIP: Looking for Fellow
Elena Dapía Díaz
International Project Manager at Foundation for Biosanitary Research and Innovation of Asturias (FINBA)
OVIEDO, (seleccione opción), Spain
Project cooperation
MSCA-PF: Head and Neck Cancer Research Group
- MSCA-PF2025
- Proposal Idea
- POSTDOCTORAL FELLOWSHIP: Looking for Fellow
Elena Dapía Díaz
International Project Manager at Foundation for Biosanitary Research and Innovation of Asturias (FINBA)
OVIEDO, (seleccione opción), Spain